CHEST Meeting Heads to Hawai‘i Amid Recognition of Environmental Impacts on Lung Health
ACCC National Oncology Conference to Focus on Reimagining Innovation in Cancer Care
Lack of Cardiovascular Trial Diversity Is an International Issue: Dr Shrilla Banerjee Gives UK Perspective
Dr Seun Ross: BCBS Health Equity Goals Across 4 Focus Areas
Vikki Walton, MBA: Bridging Health Equity Gaps Through DE&I
Transforming Health Care: Insights From Industry Leaders on Health Equity and Policy
Dr Seun Ross: Achieving Equity Is Necessary to Sustain the Health Care System
New CMS Models Target Transformation to Address Need for Health Equity
Panelists Discuss Insurance Coverage of Opill, OTC Contraceptives During KFF Webinar
NCCN Working Group Presents Health-Related Social Needs Recommendations at Policy Summit
Vikki Walton, MBA, Shares How Employers Can Improve Health Equity
Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC
Can Early EEG Monitoring Be a Good Predictive Tool for Children With Epilepsy?
Dr G. B. John Mancini on Payer System Differences Between the US and Canada
Better Data, Leadership Needed for Global Health Equity in Heart Failure
Dr Sigrun Hallmeyer: Precision Medicine Needs to Become More Efficient
Benefits of Semaglutide in Obesity-Related HFpEF Are “Transformational” at Highest BMI Levels, Additional Data Show
More Black vs White Patients Have Risk Factors for LV Hypertrophy
The Importance of Examining and Preventing Atrial Fibrillation
RECORD-MI: Real-World Study Highlights Risk of HF After a Heart Attack
Physician Bias Contributes to Already-Existing Health Inequities in Cardiology, Says Dr Shrilla Banerjee
Dr Milton Packer Shares "Extraordinary" Results From the EMPEROR Trial
In a Surprise, Study Finds Frail Elderly Have More Bleeding After Switching From VKAs to NOACs
Session on Lipids Offers New Data for Bempedoic Acid, Olpasiran
Dr Nikolaus Marx Highlights Importance of Early Screening for Comorbid Diabetes, CVD
Exploring Interventions—Including Lifestyle—to Improve Cardiorenal Outcomes
Dr Donna Fitzsimons: Hard End Points in Cardiovascular Therapy Trials Aren't the Most Important to Patients
EMPACT-MI: Is Preventing HF After Heart Attack the Next Frontier for SGLT2 Inhibitors?
Dr Steven Deitelzweig: Switching From Apixaban to Rivaroxaban Linked to Increased Risks for Patients With NVAF
Dr Javed Butler Highlights Goals, Baseline Patient Characteristics in EMPACT-MI Trial